A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy-Reference-Cited by-同舟云学术

A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy

Published:2017-09-06 Issue:55 Volume:8 Page:93633-93643
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kim Sung Han¹,Suh Yoon Seok¹,Lee Dong-Eun²,Park Boram²,Joo Jungnam²,Joung Jae Young¹,Seo Ho Kyung¹,Lee Kang Hyun¹,Chung Jinsoo¹

Affiliation:

1. Department of Urology, Center for Prostate Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea

2. Biometric Research Branch, Division of Cancer Epidemiology and Prevention, Research Institute and Hospital of National Cancer Center, Goyang, Korea

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the impact of cytoreductive surgery in patients with oligometastatic renal cell carcinoma in clinical practice;Siberian journal of oncology;2024-03-22

2. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations;Clinical & Experimental Metastasis;2024-02-16

3. External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations;2023-10-10

4. Analysis of the effect of clinical and laboratory parameters on survival in patients with metastatic renal cell cancer with intermediate prognosis according to IMDC (International mRCC Database Consortium);Urology Herald;2023-07-18

5. Comparison of prognostic factors that affect the survival of patients with metachronous and synchronous metastases of renal cell carcinoma;Urology Herald;2022-10-01